ArticleFrontiers in oncology2026
Chemoradiation after chemotherapy for metastatic cervical cancer can provide chemo-free time.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stage IVB cervical cancer is treated with a life-prolonging and palliative intent with systemic chemotherapy and immunotherapy. The purpose of this study was to evaluate the number of these patients who had an adequate response to chemotherapy to be eligible for consolidative radiosensitizing chemotherapy and radiation (chemoradiation) and subsequent outcomes. Materials and methods: This is a retrospective review of metastatic cervical cancer patients treated with chemotherapy and evaluated for treatment with consolidative pelvic chemoradiation at a single safety-net hospital system from 2016 to 2024. Demographic data and clinical information were collected from electronic medical records. Stata was used for descriptive statistical analysis. Results: 38 patients met inclusion criteria. Most patients (84%) had squamous cell histology. All patients received platinum-based chemotherapy as first line treatment, some with triplet therapy with immunotherapy (26%) or bevacizumab (42%). Twenty (53%) patients received consolidative chemoradiation. These patients had a median treatment-free interval of 13.7 months (Interquartile range (IQR) 5.3-36.5) after finishing radiation, and 7 (35%) had no evidence of disease at last follow up. Overall survival was 26.7 months (IQR 16.8-55.9). Eighteen patients (47%) progressed on first line chemotherapy and were not eligible for chemoradiation. These patients had a median overall survival of 14 months (IQR 9.1-17.6). Factors at initial presentation associated with progression of disease on first line chemotherapy and ineligibility for chemoradiation prescription for pain medications before treatment (Odds Ratio (OR) 0.17, p=0.059), and prescription for anticoagulation for venous thromboembolism prior to treatments (OR 0.02, p=0.046). Conclusion: Consolidative pelvic radiation may be considered as a treatment option for select patients with stage IVB cervical cancer. Further research is needed to identify optimal chemoradiation regimens for local disease control, improvements in quality of life and improved health outcomes in the management of metastatic cervical cancer, particularly given the increasing use of pembrolizumab as maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.